skip to Main Content

Discovery of a Molecular Switch in Pancreatic Cancer Cells that Triggers Metastatic Disease

Newsfeed image, light gray text on dark gray background
More than 62,000 people in the United States will be diagnosed with pancreatic cancer by the end of this year, with the vast majority having a deadly and aggressive subtype known as pancreatic ductal adenocarcinoma (PDA). PDA affects more than 90% of patients with pancreatic cancer and has an average 5-year survival rate of less than 10%.

Now, researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) at NewYork-Presbyterian/Columbia University Irving Medical Center have discovered a protein whose level of expression functions as a molecular switch between primary  growth and metastatic dissemination in PDA cells. The study, published online June 24 in Molecular Cell, provides key insights towards a possible treatment that can toggle this molecular switch to block the spread of the disease to other organs. Read more . . .


Back To Top